SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Jason Chesshir who wrote (1512)10/24/1998 5:19:00 PM
From: zhiwei li  Respond to of 2173
 
They have used two different clinic indicators in PII and PIII trails.
The post-meal blood glucose level was used in all PII trails, so they could get data quickly. However the level of glycated hemoglobin (HbA1c)which is a surrogate measure of glucose control over the preceding three to four months was used in all PIII trails, that is requested by FDA for approval. This strategy may have already killed the company. IMHO.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News